Found: 6
Select item for more details and to access through your institution.
Lymph node-targeted STING agonist nanovaccine against chronic HBV infection.
- Published in:
- Cellular & Molecular Life Sciences, 2024, v. 81, n. 1, p. 1, doi. 10.1007/s00018-024-05404-y
- By:
- Publication type:
- Article
In Situ Tumor Vaccination with Calcium‐Linked Degradable Coacervate Nanocomplex Co‐Delivering Photosensitizer and TLR7/8 Agonist to Trigger Effective Anti‐Tumor Immune Responses.
- Published in:
- Advanced Healthcare Materials, 2022, v. 11, n. 12, p. 1, doi. 10.1002/adhm.202102781
- By:
- Publication type:
- Article
An Intelligent Nanovehicle Armed with Multifunctional Navigation for Precise Delivery of Toll‐Like Receptor 7/8 Agonist and Immunogenic Cell Death Amplifiers to Eliminate Solid Tumors and Trigger Durable Antitumor Immunity.
- Published in:
- Advanced Healthcare Materials, 2022, v. 11, n. 12, p. 1, doi. 10.1002/adhm.202102739
- By:
- Publication type:
- Article
CpG-C ODN M362 as an immunoadjuvant for HBV therapeutic vaccine reverses the systemic tolerance against HBV.
- Published in:
- International Journal of Biological Sciences, 2022, v. 18, n. 1, p. 154, doi. 10.7150/ijbs.62424
- By:
- Publication type:
- Article
A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression.
- Published in:
- NPJ Vaccines, 2024, v. 9, n. 1, p. 1, doi. 10.1038/s41541-024-00813-3
- By:
- Publication type:
- Article
A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression.
- Published in:
- NPJ Vaccines, 2024, v. 9, n. 1, p. 1, doi. 10.1038/s41541-024-00813-3
- By:
- Publication type:
- Article